查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018720

腦腫瘤診斷與治療市場：治療方法、影像技術、腫瘤類型、腫瘤分級、患者年齡層及最終用戶分類－2026年至2032年全球市場預測

Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality, Imaging Technology, Tumor Type, Tumor Grade, Patient Age Group, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦腫瘤診斷和治療市場價值將達到 19.5 億美元，到 2026 年將成長到 21.3 億美元，到 2032 年將達到 37.3 億美元，複合年成長率為 9.66%。

主要市場統計數據
基準年 2025 19.5億美元
預計年份：2026年 21.3億美元
預測年份 2032 37.3億美元
複合年成長率 (%) 9.66%

對目前正在重塑腦腫瘤診斷和治療創新的臨床、科學和醫療保健系統趨勢進行了清晰而令人信服的概述。

腦腫瘤的診斷和治療正處於快速發展的階段，臨床緊迫性、科學創新和醫療保健系統的變革交織在一起。分子生物學和影像學的進步重新定義了臨床醫生對腫瘤的分類方式，從而能夠進行更精確的診斷分類，並指南個別化的治療策略。同時，不斷發展的外科技術、輔助放射治療以及日益豐富的標靶治療治療方法和免疫治療選擇，無論腫瘤類型或患者年齡如何，都在重塑著腦腫瘤的治療格局。

對重新定義腦腫瘤診斷和治療發展的關鍵技術、臨床和醫療保健服務變革進行詳細分析，涵蓋整個護理過程。

在腦腫瘤的診斷和治療領域，多項變革正在發生，這些變革正在全面改變醫療服務的提供方式和產品的研發方式。在診斷階段，高解析度影像和分子病理學使得超越簡單的說明性分類，能夠進行更精確的表現型分析。這種轉變有助於設計適應性臨床試驗和標靶治療策略。同時，免疫腫瘤學和細胞療法正從實驗平台發展成為可操作的臨床治療方案，這需要對安全性監測、生產規模和長期追蹤等方面進行新的考量。

評估近期關稅主導的貿易措施將如何重塑美國腦腫瘤診斷和治療的供應鏈、採購和部署趨勢。

關稅等政策干預措施可能對腦腫瘤診斷和治療的生態系統產生廣泛而累積的影響。影響成像設備、分子檢測試劑以及用於先進外科手術和細胞療法製造的專用耗材的進口措施，可能會增加直接採購成本，並延長關鍵設備的前置作業時間。這些壓力可能會波及醫院的資本投資計畫和臨床試驗的後勤物流，這可能會減緩新型診斷平台的引入，並限制先進治療方法的推廣速度。

一項富有洞察力的綜合細分分析，解釋了治療方法、影像創新、最終用戶、腫瘤類型、惡性程度和患者年齡層如何全面決定策略重點。

從細分角度觀點，我們可以更清楚地了解科學進步和商業性機會在診斷和治療領域的集中方向。在治療方法，化療、免疫療法、放射線治療、手術和標靶治療各自發揮不同的作用機轉和臨床功能。化療包括烷化劑、抗代謝藥物和含鉑類藥物，這些藥物仍然是許多治療方法的核心；而標靶治療著重於抗血管新生藥物、mTOR抑制劑和蛋白酪氨酸激酶抑制劑，這些藥物針對分子層面的脆弱性。免疫療法包括CAR-T細胞療法、查核點抑制劑和疫苗平台，這些療法推動了聯合治療的發展，並需要專門的生產和安全性監測。這些治療方法與腫瘤的生物學特性和患者因素相互作用，從而影響治療順序和臨床試驗的設計。

一份全面的區域分析報告，描述了美洲、歐洲、中東和非洲以及亞太地區如何塑造臨床引入、監管策略和商業化的路徑。

地理因素是技術採納、監管路徑和商業策略的關鍵促進因素。在美洲，臨床試驗的接受能力、創投和整合醫療網路正在推動新型診斷和治療方法的快速普及，而強大的生物技術實用化生態系統和先進的醫院基礎設施也為此提供了有力支持。尤其值得一提的是，美國仍然是早期研究和產品上市的中心，區域報銷制度和政策變化影響患者獲得治療的速度。

這份可操作的企業資料概述了策略聯盟、平台整合和製造投資如何使腦腫瘤診斷和治療開發領域的公司之間產生差異化。

該行業的企業發展趨勢以戰略聯盟、平台擴張以及對生產製造和數位化能力的定向投資為特徵。將診斷平台與治療產品線結合，或與伴隨診斷系統實現整合的公司，透過協調研發和商業化進程，正在獲得競爭優勢。在基於生物標記的患者招募和即時療效評估需求的推動下，生物製藥研發公司與診斷和影像供應商之間的合作日益活躍。

為產業領導者提供清晰且優先的建議，以加速腦腫瘤治療的研發，降低商業性風險，並證明其臨床和經濟價值。

產業領導者應制定一套切實可行的優先事項，將科學預期轉化為臨床影響和永續的經營模式。首先，應優先投資於整合診斷技術，將分子譜分析與先進影像技術結合，以實現精準的病患篩選和入組適應性臨床試驗。這種方法可以降低研發風險，並提高展現顯著臨床效益的可能性。其次，應實現價值鏈多元化，並探索區域製造夥伴關係，以確保高價值投入品的持續供應，同時減輕貿易和關稅的影響。

為了確保研究結果的可靠性，我們採用嚴謹透明的調查方法，結合文獻整合、專家訪談、臨床註冊分析和檢驗程序。

本分析的調查方法整合了多種互補途徑，以確保其穩健性、有效性和可操作性。該方法基於結構化的文獻綜述，並整合了同行評審的臨床研究、指南和公開的監管文件，從而涵蓋了目前的護理標準和新興證據。除了這些二手研究外，還輔以有針對性的一手研究，包括對臨床實驗專家、影像專家、主要研究者和供應鏈管理人員的訪談，以使研究結果更具現實意義並符合實際情況。

策略結論強調，要取得腦腫瘤治療的實質改進，需要進行綜合診斷、協作開發和實證實施。

總之，腦腫瘤的診斷和治療領域正處於一個關鍵的十字路口，技術進步、不斷演進的臨床範式和不斷變化的政策環境在此交匯，既帶來了機遇，也帶來了挑戰。整合診斷和精準醫療將是未來發展的核心，但它們的實用化取決於臨床專科、監管機構、保險公司和產業之間的通力合作。儘管影像學、分子譜分析和腫瘤免疫學的創新正在重新定義疾病分類和治療路徑，但供應鏈的韌性和策略夥伴關係對於維持和擴大醫療服務的可及性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腦腫瘤診斷與治療市場（依治療方法分類）

  • 化療
    • 烷化劑
    • 抗代謝物
    • 含鉑類藥物
  • 免疫療法
    • CAR-T細胞療法
    • 查核點抑制劑
    • 疫苗療法
  • 放射線治療
  • 外科手術
  • 分子標靶治療
    • 抗血管新生藥物
    • mTOR抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章：影像技術在腦腫瘤診斷與治療市場的應用

  • 電腦斷層掃描
  • 磁振造影
    • 擴散張量造影
    • 功能性磁振造影
    • 光譜學
  • 分子診斷
  • 正子斷層掃描
    • 胺基酸示踪劑
    • FDG
  • 超音波

第10章：依腫瘤類型分類的腦腫瘤診斷與治療市場

  • 聽神經瘤
  • 膠質瘤
  • 腦膜瘤
  • 腦下垂體瘤

第11章：依腫瘤惡性度分類的腦腫瘤診斷與治療市場

  • 優質
  • 低等級

第12章：依患者年齡層分類的腦腫瘤診斷與治療市場

  • 成人版
  • 老年人
  • 兒童

第13章：腦腫瘤診斷與治療市場：依最終使用者分類

  • 門診手術中心
  • 診斷檢查室
  • 醫院
  • 研究機構

第14章 腦腫瘤診斷與治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：腦腫瘤診斷與治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 腦腫瘤診斷與治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國腦腫瘤診斷與治療市場

第18章：中國腦腫瘤診斷與治療市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Ipsen Pharma
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Mundipharma International Limited
  • Novartis AG
  • Novocure GmbH
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • VBL Therapeutics
Product Code: MRR-CA17E905E619

The Brain Tumor Diagnosis & Therapeutics Market was valued at USD 1.95 billion in 2025 and is projected to grow to USD 2.13 billion in 2026, with a CAGR of 9.66%, reaching USD 3.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.95 billion
Estimated Year [2026] USD 2.13 billion
Forecast Year [2032] USD 3.73 billion
CAGR (%) 9.66%

A clear and compelling introduction to the current clinical, scientific, and health system forces reshaping brain tumor diagnosis and therapeutic innovation

Brain tumor diagnosis and therapeutics occupy a rapidly changing intersection of clinical urgency, scientific innovation, and health system transformation. Advances in molecular biology and imaging have reframed how clinicians classify neoplasms, enabling more precise diagnostic categories that inform individualized therapeutic strategies. At the same time, evolving surgical techniques, adjunctive radiation modalities, and a growing suite of targeted and immune-based therapies are reshaping treatment pathways across tumor types and patient age cohorts.

This landscape is defined by multidimensional collaboration among neurosurgeons, neuro-oncologists, radiologists, pathologists, and translational scientists. Technology convergence-combining genomic profiling, advanced MRI sequences, and functional imaging-now supports risk-adapted care and more informed clinical decision-making. However, significant unmet needs remain, particularly for aggressive high-grade tumors and rare pediatric variants where durable responses are limited and therapeutic windows are narrow.

Consequently, stakeholders are prioritizing integrated diagnostics and therapeutic development, with emphasis on biomarker-driven trials, minimally invasive monitoring, and real-world evidence generation. This report introduces the critical themes that govern current clinical practice, innovation trajectories, and health system adoption, setting the stage for the deeper analyses that follow and framing the practical implications for developers, providers, and payers.

Detailed analysis of the major technological, clinical, and care-delivery shifts that are redefining brain tumor diagnostics and therapeutic development across the care continuum

The landscape of brain tumor diagnosis and therapeutics is undergoing several transformative shifts that collectively alter how care is delivered and how products are developed. At the diagnostic level, high-resolution imaging and molecular pathology are moving beyond descriptive classification to enable precision phenotyping; this transition supports adaptive trial designs and targeted therapeutic strategies. Concurrently, immuno-oncology and cell-based therapies are progressing from experimental platforms to viable clinical options, prompting new considerations for safety monitoring, manufacturing scale, and long-term follow-up.

Imaging innovations, including diffusion tensor imaging, functional MRI, and amino acid PET tracers, are improving lesion characterization and treatment planning, thereby enabling more conservative resections and optimized radiation targeting. Surgical advances such as intraoperative visualization and fluorescence-guided resection are enhancing extent-of-resection while preserving function, which in turn changes adjuvant therapy decision-making. On the therapeutic front, combination regimens that pair targeted agents with immune-modulatory approaches are increasingly central to clinical development, necessitating more sophisticated biomarker strategies and companion diagnostics.

Additionally, digital health, machine learning, and real-world data are gaining prominence as tools for earlier detection, prognostic modeling, and post-market surveillance. These shifts create both opportunities and complexities: developers must navigate regulatory expectations for novel modalities while health systems must adapt infrastructure to support multidisciplinary workflows and advanced diagnostics. Transitioning from siloed innovation to integrated care pathways will determine which advances translate into meaningful improvements in patient outcomes.

Assessment of how recent tariff-driven trade measures could reshape supply chains, procurement, and adoption dynamics for brain tumor diagnostics and therapeutics in the United States

Policy interventions such as tariffs can exert a broad and cumulative influence on the ecosystem that supports brain tumor diagnostics and therapeutics. Import measures affecting imaging equipment, reagents for molecular testing, and specialized consumables used in advanced surgical and cell therapy manufacturing can increase direct procurement costs and extend lead times for critical tools. These pressures ripple through hospital capital planning and clinical trial logistics, potentially delaying adoption of newer diagnostic platforms and constraining the pace at which advanced therapeutic modalities are scaled.

Manufacturers and health systems may respond by accelerating localization of supply chains and investing in domestic manufacturing capacity for high-value inputs. While onshoring can mitigate future trade-related disruptions, it also requires significant capital investment and strategic partnerships to ensure quality and regulatory compliance. For smaller developers and academic centers, increased import costs may shift prioritization toward technologies with lower capital intensity or toward licensing agreements that reduce upfront hardware requirements.

In the research domain, tariffs can alter the economics of multicenter trials that rely on uniform imaging or molecular platforms, complicating harmonization and data comparability. Clinical collaborators may need to renegotiate service contracts or adapt protocols to account for equipment heterogeneity. Ultimately, stakeholders should view tariff-related impacts as a catalyst for supply diversification, strategic procurement, and closer collaboration between industry, clinical networks, and policy makers to safeguard access to critical diagnostic and therapeutic innovations.

Insightful segmentation synthesis explaining how therapeutic modalities, imaging innovations, end users, tumor typologies, grades, and patient age groups collectively inform strategic priorities

A segmentation-aware perspective clarifies where scientific advances and commercial opportunities are concentrated across diagnostic and therapeutic axes. Within therapeutic modality, chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy each contribute distinct mechanisms and clinical roles; chemotherapy includes alkylating agents, antimetabolites, and platinum compounds that remain core to many regimens, while targeted therapies emphasize antiangiogenic agents, mTOR inhibitors, and tyrosine kinase inhibitors focused on molecular vulnerabilities. Immunotherapy encompasses CAR T-cell therapy, checkpoint inhibitors, and vaccine platforms that are driving combination strategies and necessitating specialized manufacturing and safety monitoring. These modalities interact with tumor biology and patient factors to shape treatment sequencing and trial design.

On the diagnostic imaging side, the market is organized across computed tomography, magnetic resonance imaging, molecular diagnostics, positron emission tomography, and ultrasound. Magnetic resonance imaging further segments into diffusion tensor imaging, functional MRI, and spectroscopy that enhance structural and functional assessment, whereas positron emission tomography leverages amino acid tracers and FDG for improved metabolic evaluation. End users are defined across ambulatory surgical centers, diagnostic laboratories, hospitals, and research institutes, each exhibiting different capital intensity, workflow needs, and decision-making authority for technology adoption.

Tumor-type segmentation spans acoustic neuroma, glioma, meningioma, and pituitary tumor with divergent clinical courses and regulatory pathways, and tumor-grade classification into high grade and low grade remains pivotal for prognosis and treatment aggressiveness. Patient age cohorts-adult, geriatric, and pediatric-introduce distinct biological considerations, dosing imperatives, and regulatory protections, especially in pediatric populations where long-term neurocognitive outcomes are critical. Integrating these segmentation lenses reveals that investment and clinical emphasis are concentrated where molecularly targetable biology, unmet clinical need, and feasible delivery pathways converge.

Comprehensive regional analysis describing how Americas, Europe Middle East & Africa, and Asia-Pacific each shape clinical adoption, regulatory strategy, and commercialization pathways

Geographic dynamics are a key determinant of technology adoption, regulatory pathways, and commercial strategy. In the Americas, clinical trial capacity, venture investment, and integrated care networks drive rapid uptake of novel diagnostics and therapeutics, complemented by a strong ecosystem for biotech translation and advanced hospital infrastructure. The United States in particular remains a focal point for early-phase studies and commercial launches, with regional reimbursement and policy changes influencing speed of access.

The Europe, Middle East & Africa region exhibits heterogeneous healthcare systems and regulatory environments, with pockets of excellence in advanced neuro-oncology centers and national research networks. European regulatory frameworks emphasize rigorous evidence and cost-effectiveness, while several Gulf and North African markets are investing in tertiary care capacity, creating selective demand for high-value interventions. These variations require tailored market access strategies and localized evidence generation.

Asia-Pacific is characterized by rapid adoption curves in urban centers, growing domestic manufacturing capabilities, and demographic trends that expand demand for neuro-oncology services. Cost sensitivity and diverse reimbursement landscapes in the region necessitate flexible pricing and partnership models, while several Asian countries are emerging as key sites for late-stage clinical trials due to patient volume and operational efficiencies. Cross-regional collaboration and technology transfer are increasingly important to ensure consistent standards of care and to scale innovations globally.

Actionable corporate intelligence outlining how strategic partnerships, platform integration, and manufacturing investments differentiate companies in brain tumor diagnostics and therapeutic development

Company behavior in this sector is characterized by strategic partnerships, platform extension, and targeted investments in manufacturing and digital capabilities. Firms that combine diagnostic platforms with therapeutic pipelines or that secure companion diagnostic linkages gain competitive advantage by aligning development and commercialization timelines. Collaboration between biopharma developers and diagnostics or imaging vendors is intensifying, driven by the need for biomarker-driven enrollment and real-time response assessment.

Key corporate strategies include forming consortiums to de-risk early clinical development, outsourcing specialized manufacturing for cell and gene therapies, and investing in cloud-based platforms for imaging analysis and longitudinal outcome monitoring. Mergers and acquisitions continue to be a lever for rapid capability acquisition, particularly for companies seeking to integrate molecular testing, imaging analytics, and clinical decision support into a coherent offering. Smaller innovators are frequently acquired or enter co-development agreements to scale manufacturing and regulatory expertise, while larger organizations focus on platform consolidation and global market access.

Across the competitive landscape, agility in forging payer relationships and demonstrating health economic value is becoming as important as scientific differentiation. Companies that proactively address real-world implementation challenges, simplify clinical workflows, and provide training and support to health systems are more likely to achieve durable adoption and sustained commercial performance.

Clear and prioritized recommendations for industry leaders to accelerate development, mitigate commercial risks, and demonstrate clinical and economic value in brain tumor care

Industry leaders should adopt a set of pragmatic, actionable priorities to convert scientific promise into clinical impact and sustainable business models. First, prioritize investment in integrated diagnostics that link molecular profiling with advanced imaging to enable precise patient selection and adaptive trial enrollment. This approach reduces development risk and enhances the likelihood of demonstrating meaningful clinical benefit. Second, diversify supply chains and consider regional manufacturing partnerships to mitigate trade and tariff exposure while ensuring continuity for high-value inputs.

Third, pursue combination strategies deliberately by aligning regulatory and safety pathways early in development and by establishing standardized biomarker strategies to streamline approval and reimbursement. Fourth, engage payers and health technology assessment bodies early to define evidence requirements and case definitions that support value-based contracting. Fifth, invest in real-world evidence and data infrastructure that captures longitudinal outcomes, quality-of-life metrics, and health economic endpoints to support uptake and formulary inclusion.

Finally, strengthen cross-sector collaborations with academic centers, patient advocacy organizations, and surgical and radiology networks to accelerate clinical adoption, improve trial recruitment, and ensure that innovations address practical care delivery constraints. These steps will help organizations reduce time to market, enhance value demonstration, and ultimately improve patient outcomes in a complex therapeutic area.

Rigorous and transparent research methodology combining literature synthesis, expert interviews, clinical registry analysis, and validation steps to ensure trustworthy insights

The research methodology underpinning this analysis integrates multiple complementary approaches to ensure robustness, validity, and practical relevance. The foundation comprises structured literature review and synthesis of peer-reviewed clinical studies, guidelines, and publicly available regulatory documents to capture the current standard of care and emergent evidence. This secondary research is augmented with targeted primary research, including interviews with clinical experts, imaging specialists, trial investigators, and supply chain managers to contextualize findings and confirm operational realities.

Data triangulation is used to reconcile differing inputs and to validate thematic conclusions. Clinical trial registries and recent conference proceedings are reviewed to map active development programs and to identify nascent therapeutic and diagnostic trends. Where appropriate, technical specifications and product labeling are analyzed to understand capabilities, limitations, and integration requirements. The methodology also includes scenario analysis to test how variables such as regulatory shifts, reimbursement changes, or supply-chain disruptions might affect adoption curves.

Limitations are acknowledged, including variability in regional practice patterns and the evolving nature of early-phase clinical evidence. To address these constraints, findings are presented with clarity about evidence level and are supplemented by expert judgment. Ethical standards and data integrity practices guide all primary engagements, and confidential input from experts is synthesized to preserve anonymity while preserving actionable insight.

Strategic conclusion emphasizing the need for integrated diagnostics, coordinated development, and evidence-driven adoption to realize meaningful improvements in brain tumor care

In conclusion, the field of brain tumor diagnosis and therapeutics stands at a pivotal juncture where converging technological advances, evolving clinical paradigms, and shifting policy environments create both opportunity and complexity. Integrated diagnostics and precision-directed therapeutics are central to future progress, but their successful translation will depend on coordinated efforts across clinical specialties, regulators, payers, and industry. Innovations in imaging, molecular profiling, and immuno-oncology are redefining disease classification and treatment pathways, while supply-chain resilience and strategic partnerships are essential to sustain access and scale.

Stakeholders that invest in linkage between diagnostics and therapeutics, proactively manage commercial and regulatory risk, and prioritize real-world evidence generation will be best positioned to realize durable clinical and economic outcomes. The imperative is to move beyond isolated breakthroughs toward systems-level integration that improves patient selection, optimizes therapeutic sequencing, and preserves quality of life. Doing so will require disciplined execution, clear demonstration of value, and a patient-centered focus that aligns scientific ambition with deliverable clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Tumor Diagnosis & Therapeutics Market, by Therapeutic Modality

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Platinum Compounds
  • 8.2. Immunotherapy
    • 8.2.1. CAR T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccine Therapy
  • 8.3. Radiation Therapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Antiangiogenic Agents
    • 8.5.2. MTOR Inhibitors
    • 8.5.3. Tyrosine Kinase Inhibitors

9. Brain Tumor Diagnosis & Therapeutics Market, by Imaging Technology

  • 9.1. Computed Tomography
  • 9.2. Magnetic Resonance Imaging
    • 9.2.1. Diffusion Tensor Imaging
    • 9.2.2. Functional MRI
    • 9.2.3. Spectroscopy
  • 9.3. Molecular Diagnostics
  • 9.4. Positron Emission Tomography
    • 9.4.1. Amino Acid Tracers
    • 9.4.2. FDG
  • 9.5. Ultrasound

10. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Type

  • 10.1. Acoustic Neuroma
  • 10.2. Glioma
  • 10.3. Meningioma
  • 10.4. Pituitary Tumor

11. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Grade

  • 11.1. High Grade
  • 11.2. Low Grade

12. Brain Tumor Diagnosis & Therapeutics Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Brain Tumor Diagnosis & Therapeutics Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals
  • 13.4. Research Institutes

14. Brain Tumor Diagnosis & Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Brain Tumor Diagnosis & Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Brain Tumor Diagnosis & Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Brain Tumor Diagnosis & Therapeutics Market

18. China Brain Tumor Diagnosis & Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Agios Pharmaceuticals, Inc.
  • 19.7. Amgen Inc.
  • 19.8. AstraZeneca PLC
  • 19.9. Bayer AG
  • 19.10. Bristol Myers Squibb Company
  • 19.11. Eli Lilly and Company
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. GlaxoSmithKline plc
  • 19.14. Ipsen Pharma
  • 19.15. Johnson & Johnson
  • 19.16. Karyopharm Therapeutics Inc.
  • 19.17. Merck & Co., Inc.
  • 19.18. Mundipharma International Limited
  • 19.19. Novartis AG
  • 19.20. Novocure GmbH
  • 19.21. Pfizer Inc.
  • 19.22. Sanofi S.A.
  • 19.23. Takeda Pharmaceutical Company Limited
  • 19.24. VBL Therapeutics

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ANTIANGIOGENIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIFFUSION TENSOR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FUNCTIONAL MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMINO ACID TRACERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY FDG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ACOUSTIC NEUROMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GLIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PITUITARY TUMOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 241. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 242. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GCC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TUMOR GRADE, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 272. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 276. G7 BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2032 (USD MILLION)
  • TABLE 277. G7 BRAIN TUMOR DIAGNO